Drug Profile
GBS NN
Alternative Names: GBS NN/NN2; GBS vaccine - Minervax; GBS-NN/NN2 vaccine; Group B Streptococcal vaccine - Minervax; Streptococcal B vaccine - MinervaxLatest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Lund University
- Developer Minervax
- Class Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Streptococcal infections
Most Recent Events
- 27 Jun 2023 MinervaX completes enrolment in its phase I trial in Streptococcal infections (Prevention, In the elderly) in Belgium (IM) (NCT05782179)
- 01 Mar 2023 Phase-I clinical trials in Streptococcal infections (Prevention, In the elderly) in Belgium (IM) (NCT05782179)
- 05 Jan 2023 GBS NN receives Fast track status from the US FDA for Streptococcal infections